Research shows limited impact of ban on flavored e-cigarettes

Dec.01.2022
Research shows limited impact of ban on flavored e-cigarettes
The US ban on flavored e-cigarettes has had limited effectiveness, as users turn to alternative products and flavors.

On February 6, 2020, the United States Food and Drug Administration banned the sale of several flavors of electronic cigarettes, with some significant exceptions.


According to a survey published in the journal "Tobacco Control," out of 3500 adult users of electronic cigarettes who were surveyed, less than 5% of them stopped using electronic cigarettes due to the ban on flavored e-cigarettes. The remaining respondents switched to other types or flavors of electronic cigarettes or other tobacco products that were not covered by the ban.


More and more literature suggests that the flavorings in e-cigarettes can cause harm when inhaled, making a ban on these flavorings reasonable, according to tobacco research expert and Professor of Public Health Sciences and Community Center Deborah J. Ossip. "But bans don't seem to be effective. People, including young people, can still access flavored products and are still using them," she added. This statement was made at the University of Rochester Medical Center's Department of Public Health and Prevention.


According to Dongmei Li, the lead author of the study and associate professor of clinical and translational research, obstetrics and gynecology, and public health sciences, a significant part of the problem is that the ban does not cover newer products such as disposable e-cigarette pods and e-cigarette pods that use canisters instead of cartridges/boxes.


Other forms of flavored electronic cigarettes, particularly disposable ones, have become very popular after FDA policies were implemented," said Li. "The FDA's policies did not prohibit products with mint or tobacco flavors - our research indicates that many people switched to mint-flavored e-cigarettes after the ban. It seems that many people find menthol to be a favorable taste.


According to this study, nearly 30% of the survey respondents switched to canned or disposable flavored e-cigarettes, and another 30% switched to mint or tobacco flavored pods. Some reported turning to traditional tobacco products: 14% switched to combustible products like cigarettes, and 5% switched to smokeless products such as chewing or dipping tobacco. Less than 5% of respondents stopped using e-cigarettes after the FDA ban.


Researchers used statistical models to identify factors related to changes in e-cigarette usage behavior. They found a close correlation between using tank system e-cigarettes and switching to other flavors not regulated by the FDA's flavor law enforcement policies.


The use of mint-flavored electronic cigarettes over the past 30 days is associated with switching to mint-flavored electronic cigarettes. Those who reported smoking every day or every few days were more likely to switch to tobacco-flavored electronic cigarettes or combustible tobacco products.


On the other hand, people who use flavored electronic cigarettes without nicotine are more likely to quit smoking. Although the study was not intended to establish a causal relationship, the association supports previous research showing that reducing nicotine levels in cigarettes can help smokers quit. However, further research is needed to better understand the relationship between the use of low-nicotine electronic cigarettes and smoking cessation.


Looking towards the future, Li Dongmei believes that if this policy covers all flavors of electronic cigarettes (including mint and all types of electronic cigarettes) and actively monitors the implementation and compliance of the policy, then the policy may be effective. "Both are important in reducing the popularity of electronic cigarettes among young people in the United States," she said.


2FIRSTS will continue to cover this topic, with updates available on the "2FIRSTS APP". Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | PMI Launches TEREA Black Mint Pearl in Japan, Adding First Capsule Variant to Black Range With Nationwide Rollout From October 19
Product | PMI Launches TEREA Black Mint Pearl in Japan, Adding First Capsule Variant to Black Range With Nationwide Rollout From October 19
Philip Morris Japan (PMJ) launched TEREA Black Mint Pearl on October 15, 2026, introducing the first capsule-equipped heated tobacco stick in the TEREA Black range for IQOS ILUMA devices. The product combines a strong menthol profile with a crushable mint capsule and is priced at ¥640 per 20-stick pack, including tax. Sales began at four IQOS stores and selected retail partners on October 15, with distribution expanding to convenience stores and other tobacco retailers nationwide from October 19. The launch brings Japan's TEREA portfolio to 28 variants, including 21 menthol-related products, or 75% of the range.
product
Oct.16 by 2Firsts Perspectives
Malaysia Liquid Nicotine Returns to Poisons List, Leaving Vape Retail and RM354 Million Tax Collection in Legal Uncertainty
Malaysia Liquid Nicotine Returns to Poisons List, Leaving Vape Retail and RM354 Million Tax Collection in Legal Uncertainty
Malaysia’s withdrawal of its appeal in a landmark liquid-nicotine case has left a High Court ruling that struck down the 2023 nicotine exemption in force, bringing liquid and gel nicotine used in vaping products back under the Poisons Act 1952. At the same time, the Control of Smoking Products for Public Health Act 2024 continues to provide a regulatory framework for vaping products, creating uncertainty over retail sales, taxation and existing inventory. MPs are calling for nicotine vape sales and excise collection to stop, including refunds of more than RM354 million collected since 2023, while industry and consumer groups are asking the government to clarify the current legal position.
Sep.04
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India's Ministry of Health and Family Welfare has directed states to step up enforcement against nicotine pouch sales, citing increased availability through online and offline channels and concern about nicotine exposure among children. Reuters reported that international brands including ZYN and White Fox are being sold in India. A study led by ICMR-NICPR found pouches in seven of 10 surveyed locations and identified 68 brands and 445 flavors online. Separately, India's Drugs Technical Advisory Board recommended in August that no new nicotine formulation be approved.
Regulations
Sep.28 by 2Firsts Perspectives
Product | JTI Launches Ploom AURA Teal Electric Pop in South Korea, Its First Dual-Color Edition
Product | JTI Launches Ploom AURA Teal Electric Pop in South Korea, Its First Dual-Color Edition
JTI Korea launched the Ploom AURA Teal Electric Pop limited edition in South Korea on September 1, 2026, marking the first dual-color design in the Ploom AURA range. The device combines a dark green body with teal accents and is accompanied by matching Front Panel, Back Cover and Pocket Bag accessories. The standalone device is priced at KRW 29,000, with three additional device-and-accessory bundles available. The release continues JTI Korea's use of limited colorways and interchangeable accessories to expand the Ploom AURA portfolio without introducing a new hardware platform.
Sep.03
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08